These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33034579)

  • 1. COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
    Şen S; Üresin AY
    Turk Kardiyol Dern Ars; 2020 Oct; 48(7):631-634. PubMed ID: 33034579
    [No Abstract]   [Full Text] [Related]  

  • 2. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
    Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
    J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments.
    Cao Z; Wu Y; Faucon E; Sabatier JM
    Infect Disord Drug Targets; 2020; 20(3):348-349. PubMed ID: 32370727
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 6. [ACE2 and coronavirus - a question of balance and dynamics?].
    Lundström A; Sandén P
    Lakartidningen; 2020 Apr; 117():. PubMed ID: 32314329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
    South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
    Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
    Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
    mBio; 2020 May; 11(3):. PubMed ID: 32444383
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
    Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
    Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
    [No Abstract]   [Full Text] [Related]  

  • 11. [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?].
    Pechère-Bertschi A; Ponte B; Wuerzner G
    Rev Med Suisse; 2020 May; 16(693):1003-1007. PubMed ID: 32401442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
    Vikse J; Henry BM
    Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
    [No Abstract]   [Full Text] [Related]  

  • 13. Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.
    Hrenak J; Zorad S; Simko F
    Gen Physiol Biophys; 2020 May; 39(3):203-204. PubMed ID: 32525813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.
    Zheng YY; Ma YT; Zhang JY; Xie X
    Nat Rev Cardiol; 2020 May; 17(5):313-314. PubMed ID: 32231330
    [No Abstract]   [Full Text] [Related]  

  • 17. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
    Tseng YH; Yang RC; Lu TS
    Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
    Speth RC
    Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 and the pulmonary vascular injury.
    Dai HL; Guang XF
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972276. PubMed ID: 33176538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.